INTERVIEW | Dr James Campbell on Proactive
0
Patrys CEO and MD, Dr James Campbell, was interviewed by Andrew Scott from Proactive about new preclinical data for its…
PAT-DX3 Crosses Blood Brain Barrier in Healthy Animals
Patrys has today released new preclinical data that supports the potential of Patrys’ full-sized IgG antibody, PAT-DX3, to deliver payloads…
Stockhead Investor Guide
Patrys has been featured as part of the innovative and vibrant Australian biotech sector in the Stockhead Investor Guide to…
INTERVIEW | Dr James Campbell on Proactive
Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott to discuss the importance of today’s announcement that…
PAT-DX1 Engineering Run Update
Patrys’ appointed Contract Development Manufacturing Organisation (CDMO) has successfully completed specification testing of PAT-DX1 drug substance produced in the recently-completed…
New Research Grant For Deoxymabs in Metastatic Breast Cancer
Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian…
PAT-DX1 Improves Survival in Animal Model of Brain Cancer
Patrys is pleased to share promising new preclinical research results today. A new animal study has found that PAT-DX1, in…
Retirement of Non-Executive Chair
Patrys has today announced that the Company’s long-standing Chair, Mr John Read, will be retiring as the Non-Executive Chair, and…
Quarterly Activities Report & 4C – 30 June 2022
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
PAT-DX1 Engineering Run Successfully Completed
Patrys has today announced a positive update on the second engineering run for its lead asset PAT-DX1, a critical step…